Ultragenyx Q1 Revenue Misses Estimates by 14%, Net Loss Widens
RARE sits 31% above its 52-week low of $18.29.
Summary
Ultragenyx Pharmaceutical reported first-quarter revenue of $136 million, falling significantly short of analyst expectations of $158.78 million, representing a 14.3% miss. The company also posted a wider net loss of $185 million, or $1.84 per share. This financial underperformance comes after the company's recent 10-K highlighted challenges including a Phase 3 study failure and an Incomplete Response Letter for a gene therapy BLA. The substantial revenue miss for the quarter is a clear negative surprise for investors, indicating weaker-than-expected immediate operational performance. While the company reaffirmed its full-year 2026 revenue and expense guidance and maintained its 2027 profitability target, the Q1 miss could still pressure the stock in the short term. Traders will be looking for signs of recovery in subsequent quarters and further details on how the company plans to achieve its reaffirmed annual guidance despite the weak start.
At the time of this announcement, RARE was trading at $24.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $18.29 to $42.37. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.